GO:0043130 ubiquitin binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043130 (ubiquitin binding) describes the molecular function of non-covalent binding to ubiquitin, a small protein that marks other proteins for degradation.
• Ubiquitin-binding domains (UBDs) are structurally diverse modules that recognize distinct ubiquitin chain linkages and regulate signaling, trafficking, and DNA repair [1, 6].
• Linkage specificity of UBDs and deubiquitinases is critical for decoding the ubiquitin code and is determined by structural features.
• Ubiquitin binding is essential for the DNA damage response, where UBD-containing proteins such as SPRTN and those with UBZ domains coordinate repair [7, 8].
• Dysregulation of ubiquitin binding contributes to cancer, neurodegeneration, and inflammatory diseases, making it a therapeutic target [3, 4].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable functional dissection of ubiquitin-binding proteins in disease contexts [3, 7].
Description
Ubiquitin binding (GO:0043130) is a molecular function defined as the non-covalent interaction with ubiquitin, a highly conserved 76-amino-acid protein that can be covalently attached to other proteins to mark them for proteasomal degradation. This binding event is mediated by ubiquitin-binding domains (UBDs), which are found in hundreds of human proteins and decode the ubiquitin signal into diverse cellular outcomes [1, 6]. The importance of ubiquitin binding extends beyond degradation: it regulates protein trafficking, DNA damage repair, immune signaling, and cell cycle progression [2, 8]. Researchers study ubiquitin binding to understand how cells interpret the ubiquitin code and how its disruption leads to disease [5, 6]. The specificity of ubiquitin binding is determined by the type of ubiquitin chain linkage (e.g., K48, K63, linear) and the structural features of the UBD [1, 6]. This article provides a comprehensive overview of the mechanisms, key genes, and research methods for studying GO:0043130, with a focus on CRISPR-based models and therapeutic implications.
ubiquitin binding At A Glance
| GO ID | GO:0043130 |
|---|---|
| GO term | ubiquitin binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Non-covalent binding to ubiquitin, decoding ubiquitin signals for degradation, trafficking, and signaling [1, 6] |
| Definition source | QuickGO |
| Related domains | UBDs such as UBA, UBZ, UIM, NZF, and linear ubiquitin chain-binding domains [1, 8] |
| Linkage specificity | Recognizes distinct polyubiquitin linkages (K48, K63, linear) to determine downstream fate |
| Disease relevance | Cancer, neurodegeneration, inflammatory diseases [3, 4, 8] |
What Is GO:0043130?
GO:0043130 (ubiquitin binding) is the molecular function of selectively interacting with ubiquitin, a protein that when covalently bound to other cellular proteins marks them for proteolytic degradation. This binding is non-covalent and is typically mediated by ubiquitin-binding domains (UBDs) that recognize ubiquitin or polyubiquitin chains with varying linkage specificities [1, 6].
Why Is ubiquitin binding Important in Cell Biology?
Ubiquitin binding is a central mechanism for translating the ubiquitin code into cellular responses, and its dysregulation is implicated in a wide range of human diseases, including cancer, neurodegenerative disorders, and inflammatory conditions [3, 4, 8]. Understanding ubiquitin binding is therefore essential for developing targeted therapies that modulate ubiquitin-dependent pathways.
• Regulates protein degradation via the proteasome, controlling turnover of key regulatory proteins.
• Coordinates DNA damage repair through UBD-containing proteins like SPRTN and UBZ-domain proteins [7, 8].
• Controls endosomal sorting and trafficking via ESCRT components that bind ubiquitinated cargo.
• Modulates immune signaling by recognizing linear ubiquitin chains in NF-kB activation.
• Determines specificity of deubiquitinases (DUBs) that counteract ubiquitination [5, 6].
• Involved in cancer progression through E3 ligases like DTX3L and their binding partners.
• Contributes to glomerulonephritis via regulation of NR4A1 stability.
• Provides targets for therapeutic intervention in neurodegeneration and cancer [3, 8].
• Essential for maintaining proteostasis and cellular stress responses.
• Enables spatiotemporal control of DNA-protein crosslink repair by SPRTN.
Molecular Mechanism of ubiquitin binding
Recognition of ubiquitin and chain linkage
In simple terms: Ubiquitin-binding domains act like hands that grab ubiquitin tags, and different hands prefer different tag shapes.
Ubiquitin-binding domains (UBDs) recognize ubiquitin or polyubiquitin chains with high specificity. Structural studies have revealed that UBDs such as UBA, UBZ, UIM, and NZF domains bind to the hydrophobic patch of ubiquitin (Ile44, Leu8, Val70) and can discriminate between different chain linkages [1, 6]. Linear ubiquitin chain-binding domains specifically recognize M1-linked chains, which are important for NF-kB signaling. The linkage specificity is encoded by the arrangement of ubiquitin units and the complementary surface of the UBD.
Structural basis of linkage specificity
In simple terms: The shape of the ubiquitin chain determines which proteins can bind it.
The structural basis for linkage specificity has been elucidated for several UBDs and deubiquitinases. For example, the NZF domain of TAB2 binds K63-linked chains, while the UBZ domain of Polη binds monoubiquitin. The orientation and spacing of ubiquitin units in K48 versus K63 chains create distinct interaction surfaces that are recognized by specific UBDs. This specificity ensures that different ubiquitin signals lead to distinct cellular outcomes.
Cofactors and regulation of ubiquitin binding
In simple terms: Other proteins can help or hinder the binding of ubiquitin to its partners.
Ubiquitin binding can be regulated by post-translational modifications of either ubiquitin or the UBD-containing protein. Phosphorylation of ubiquitin at Ser65 by PINK1 modulates its interaction with Parkin, affecting mitophagy. Additionally, the ubiquitin-binding machinery itself is controlled by ubiquitination, as seen in early ESCRT components. Deubiquitinases (DUBs) can remove ubiquitin chains, thereby terminating binding interactions and recycling ubiquitin.
Functional consequences of ubiquitin binding
In simple terms: Once a protein grabs ubiquitin, it can trigger many different cellular actions.
The functional outcomes of ubiquitin binding are diverse and depend on the context. Binding of K48-linked chains typically targets proteins for proteasomal degradation. In contrast, K63-linked chains regulate DNA repair, endocytosis, and NF-kB signaling [6, 8]. Linear ubiquitin chains are recognized by NEMO to activate NF-kB. SPRTN uses dual ubiquitin binding to rapidly degrade DNA-protein crosslinks, highlighting the spatiotemporal control of ubiquitin binding.
Disease implications of altered ubiquitin binding
In simple terms: When ubiquitin binding goes wrong, it can lead to diseases like cancer and neurodegeneration.
Mutations or dysregulation of UBD-containing proteins are linked to various diseases. For instance, DTX3L, an E3 ligase with ubiquitin-binding activities, is implicated in cancer. Bruceine A protects NR4A1 from ubiquitin-mediated degradation, alleviating mesangial proliferative glomerulonephritis, demonstrating the therapeutic potential of targeting ubiquitin binding. In neurodegeneration, impaired ubiquitin binding contributes to protein aggregation and neuronal death.
Key Genes Involved in GO:0043130 ubiquitin binding
The following genes encode proteins that directly mediate or regulate ubiquitin binding (GO:0043130) and are frequently studied in disease and cellular signaling contexts.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SQSTM1/p62 | UBA domain binds K48- and K63-linked ubiquitin; autophagy receptor | Neurodegeneration, cancer, Paget disease |
| NBR1 | UBA domain binds ubiquitin; selective autophagy | Cancer, autophagy research |
| OPTN | UBAN domain binds linear and K63 chains; NF-kB and autophagy | Glaucoma, ALS [1, 8] |
| NEMO/IKBKG | UBAN domain binds linear ubiquitin; NF-kB activation | Immunodeficiency, cancer |
| TAB2/TAB3 | NZF domain binds K63-linked ubiquitin; TAK1 activation | Inflammation, cancer |
| RAP80 | UIM domains bind K63-linked ubiquitin; DNA damage response | Breast cancer, DNA repair |
| SPRTN | UBZ domain binds ubiquitin; DNA-protein crosslink repair | DNA repair, cancer |
| POLH | UBZ domain binds monoubiquitin; translesion synthesis | Xeroderma pigmentosum |
| DTX3L | E3 ligase with ubiquitin-binding domains; ADP-ribosylation | Cancer, immune signaling |
| USP7 | Deubiquitinase with ubiquitin-binding domains; p53 regulation | Cancer, neurodevelopment |
| BRCA1 | UIM domain binds ubiquitin; DNA repair | Breast and ovarian cancer |
| VPS27 | UIM domain binds ubiquitin; endosomal sorting | ESCRT pathway |
| STAM1/2 | UIM domain binds ubiquitin; ESCRT-0 component | Endosomal trafficking |
| HRS | UIM domain binds ubiquitin; ESCRT-0 component | Endosomal sorting |
| RNF168 | Ubiquitin-binding domains; DNA damage response | Immunodeficiency, cancer |
| ABIN1 | UBAN domain binds linear ubiquitin; NF-kB regulation | Autoimmunity |
| Parkin | UBD binds phosphorylated ubiquitin; mitophagy | Parkinson's disease |
How Is ubiquitin binding Regulated?
Ubiquitin binding is regulated at multiple levels. Post-translational modifications of ubiquitin itself, such as phosphorylation at Ser65 by PINK1, can alter binding affinities and downstream signaling. The ubiquitin-binding machinery is also controlled by ubiquitination, as seen in early ESCRT components where ubiquitination of the UBD-containing proteins modulates their function. Deubiquitinases (DUBs) provide a counter-regulatory mechanism by removing ubiquitin chains, thereby terminating binding interactions and recycling ubiquitin. Additionally, the expression levels of UBD-containing proteins are tightly regulated transcriptionally and post-transcriptionally to maintain cellular homeostasis.
ubiquitin binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DTX3L | Cancer (e.g., breast, prostate) | Knockout and overexpression in cancer cell lines |
| Parkin (PRKN) | Parkinson's disease | Point mutation knock-in in iPSC-derived neurons |
| SQSTM1/p62 | ALS, Paget disease | Knockout in motor neurons |
| NEMO (IKBKG) | Immunodeficiency, autoinflammation | Knock-in of linear ubiquitin-binding mutations |
| SPRTN | DNA repair deficiency, cancer | Knockout and tagged knock-in for live imaging |
Ubiquitin binding in cancer
Altered ubiquitin binding is a hallmark of many cancers. DTX3L, an E3 ubiquitin ligase with ubiquitin-binding domains, is overexpressed in several cancers and promotes tumor progression by regulating DNA repair and immune signaling. Mutations in UBD-containing proteins such as BRCA1 and RAP80 impair DNA damage repair, leading to genomic instability and cancer predisposition. Targeting ubiquitin-binding interactions is therefore a promising therapeutic strategy.
Ubiquitin binding in neurodegeneration
Neurodegenerative diseases often feature impaired ubiquitin binding and protein aggregation. In Parkinson's disease, mutations in Parkin, a UBD-containing E3 ligase, disrupt mitophagy and lead to dopaminergic neuron loss. Similarly, dysfunction of p62/SQSTM1, which binds ubiquitinated cargo for autophagy, contributes to ALS and Alzheimer's disease. These findings highlight the importance of ubiquitin binding in neuronal proteostasis.
Ubiquitin binding in inflammatory and kidney diseases
Linear ubiquitin chain binding by NEMO is essential for NF-kB activation, and its dysregulation causes immunodeficiency and autoinflammation. In mesangial proliferative glomerulonephritis, Bruceine A protects NR4A1 from ubiquitin-mediated degradation, suggesting that modulating ubiquitin binding can alleviate renal inflammation. These examples underscore the broad impact of ubiquitin binding on human health [1, 4].
From ubiquitin binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a UBD-containing gene affect DNA repair? | Knockout cell lines (e.g., SPRTN KO) |
| How does a disease-associated point mutation alter ubiquitin binding? | Point mutation knock-in (e.g., Parkin S65A) |
| Where does a UBD protein localize upon DNA damage? | Tagged knock-in (e.g., GFP-SPRTN) |
| Does overexpression of DTX3L promote tumor growth? | Overexpression in cancer cell lines |
| Which ubiquitin chain linkages are recognized by a UBD? | In vitro binding assays with mutant ubiquitin |
| Can CRISPR screening identify novel ubiquitin-binding regulators? | Genome-wide CRISPR library screening |
How to Study the ubiquitin binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NMR spectroscopy | Atomic structure and dynamics of UBD-ubiquitin complexes | Linkage specificity studies |
| Isothermal titration calorimetry | Binding affinity (Kd) between UBD and ubiquitin | Quantifying interaction strength |
| Co-immunoprecipitation | In vivo interaction between UBD proteins and ubiquitin | Endogenous complex detection |
| Fluorescence microscopy | Subcellular localization of UBD proteins | DNA damage foci formation |
| CRISPR knockout screening | Genes required for ubiquitin-dependent pathways | Cancer drug resistance |
| DiGly proteomics | Global ubiquitination sites | Mapping ubiquitin signaling |
| In vitro ubiquitination assays | Enzymatic activity of E3 ligases and DUBs | Mechanistic studies |
| Surface plasmon resonance | Real-time binding kinetics | Linkage preference profiling |
Structural and biophysical methods
Nuclear magnetic resonance (NMR) and X-ray crystallography are used to determine the atomic structures of UBDs in complex with ubiquitin, revealing linkage specificity. Isothermal titration calorimetry (ITC) and surface plasmon resonance (SPR) quantify binding affinities.
Cell-based assays for ubiquitin binding
Co-immunoprecipitation and pull-down assays with ubiquitin chains or ubiquitin-binding domains detect interactions in cell lysates. Fluorescence microscopy of tagged ubiquitin and UBD proteins visualizes co-localization at sites of DNA damage or endosomes.
CRISPR-based functional genomics
Genome-wide CRISPR knockout screens identify genes required for ubiquitin-dependent processes, such as DNA repair or NF-kB activation. Point mutation knock-in models dissect the contribution of specific ubiquitin-binding residues to disease phenotypes.
Proteomic approaches
Mass spectrometry-based proteomics using ubiquitin chain enrichment identifies proteins that bind specific linkages. DiGly proteomics maps ubiquitination sites and can be combined with UBD pulldowns to study ubiquitin signaling networks.
How CRISPR Can Be Used to Study GO:0043130 ubiquitin binding
Knockout
CRISPR knockout of UBD-containing genes (e.g., SPRTN, DTX3L) ablates ubiquitin binding and reveals loss-of-function phenotypes in DNA repair, autophagy, or cancer cell proliferation [3, 7]. Knockout cell lines are essential for validating the role of ubiquitin binding in specific pathways.
Point Mutation
Point mutation knock-in introduces disease-associated or functionally critical mutations (e.g., in the ubiquitin-binding domain of Parkin or NEMO) to dissect the contribution of individual residues to ubiquitin binding and downstream signaling [1, 5].
Knock-in
Tagged knock-in (e.g., GFP or HA tags) enables live-cell imaging and proteomic analysis of UBD proteins at endogenous expression levels, providing spatiotemporal insights into ubiquitin binding dynamics.
Overexpression
Overexpression of wild-type or mutant UBD proteins (e.g., DTX3L, p62) is used to test gain-of-function effects, such as enhanced tumor growth or altered autophagy, and to identify dominant-negative phenotypes [3, 8].
How EDITGENE Supports ubiquitin binding Research
Researchers studying ubiquitin binding-related genes often need to determine whether a candidate gene is causally involved in a specific pathway or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling functional validation of ubiquitin-binding proteins.
Contact EDITGENE today to design your custom CRISPR model for ubiquitin binding research.
Frequently Asked Questions About ubiquitin binding
What is GO:0043130?
GO:0043130 is the Gene Ontology molecular function term for ubiquitin binding, defined as binding to ubiquitin, a protein that marks other proteins for degradation.
What genes are involved in ubiquitin binding?
Genes encoding ubiquitin-binding domains include SQSTM1, NBR1, OPTN, NEMO, TAB2, RAP80, SPRTN, POLH, DTX3L, and many others [1, 3, 6, 7, 8].
What are ubiquitin-binding domains?
Ubiquitin-binding domains (UBDs) are structurally diverse protein modules (e.g., UBA, UBZ, UIM, NZF) that non-covalently recognize ubiquitin or polyubiquitin chains [1, 6].
How does ubiquitin binding lead to protein degradation?
Binding of K48-linked polyubiquitin chains by UBD-containing proteins targets the substrate to the proteasome for degradation.
What is the role of ubiquitin binding in DNA repair?
UBDs in proteins like SPRTN, RAP80, and BRCA1 recognize ubiquitin signals at DNA damage sites and recruit repair factors [7, 8].
Which diseases are linked to defective ubiquitin binding?
Cancer, neurodegeneration (Parkinson's, ALS), immunodeficiency, and inflammatory diseases are associated with altered ubiquitin binding [3, 4, 5, 8].
How can I study ubiquitin binding using CRISPR?
CRISPR knockout, point mutation knock-in, tagged knock-in, and overexpression models allow functional dissection of UBD proteins in cells [3, 5, 7].
What methods detect ubiquitin binding?
Co-immunoprecipitation, pull-down assays, NMR, ITC, SPR, and fluorescence microscopy are commonly used [1, 6, 7].
What is the difference between ubiquitin binding and ubiquitination?
Ubiquitin binding is non-covalent interaction with ubiquitin, while ubiquitination is the covalent attachment of ubiquitin to a substrate.
Why is linkage specificity important in ubiquitin binding?
Different polyubiquitin linkages (K48, K63, linear) recruit distinct UBD proteins and determine the downstream cellular outcome.
Conclusion
Ubiquitin binding (GO:0043130) is a fundamental molecular function that decodes the ubiquitin code to regulate protein degradation, DNA repair, signaling, and trafficking. Its dysregulation is implicated in cancer, neurodegeneration, and inflammatory diseases, making it a prime target for therapeutic intervention. CRISPR-based models and advanced biophysical methods continue to unravel the complexities of ubiquitin binding, offering new opportunities for drug discovery and precision medicine.
References
- 1. Fennell LM et al.. 2018. Linear ubiquitin chain-binding domains.. FEBS J 285(15):2746-2761 PMID: 29679476
- 2. Korbei B. 2022. Ubiquitination of the ubiquitin-binding machinery: how early ESCRT components are controlled.. Essays Biochem 66(2):169-177 PMID: 35352804
- 3. Vela-Rodríguez C et al.. 2022. Activities and binding partners of E3 ubiquitin ligase DTX3L and its roles in cancer.. Biochem Soc Trans 50(6):1683-1692 PMID: 36421918
- 4. Hu H et al.. 2025. Bruceine A protects nuclear receptor 4A1 from ubiquitin-degradation to alleviate mesangial proliferative glomerulonephritis.. Signal Transduct Target Ther 10(1):397 PMID: 41345104
- 5. Mevissen TET et al.. 2017. Mechanisms of Deubiquitinase Specificity and Regulation.. Annu Rev Biochem 86:159-192 PMID: 28498721
- 6. Sato Y. 2022. Structural basis for the linkage specificity of ubiquitin-binding domain and deubiquitinase.. J Biochem 172(1):1-7 PMID: 35394523
- 7. Song W et al.. 2025. The dual ubiquitin binding mode of SPRTN secures rapid spatiotemporal proteolysis of DNA-protein crosslinks.. Nucleic Acids Res 53(13) PMID: 40685547
- 8. Hofmann K. 2009. Ubiquitin-binding domains and their role in the DNA damage response.. DNA Repair (Amst) 8(4):544-56 PMID: 19213613
